Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
연구 개요
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- 스폰서
- 리드: 리제네론
- 적응증
- Atrial Fibrillation (AF)
- 중재
- REGN7508, Apixaban, Placebo
- 목표 등록
- 15,364명
- 시작일
- 2026-07-31
- 완료(예정)
- 2029-12-10
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.